BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $24.40.

BBOT has been the subject of several research reports. UBS Group cut BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. JPMorgan Chase & Co. cut their target price on shares of BridgeBio Oncology Therapeutics from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. Oppenheimer assumed coverage on BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price target on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $23.00 price target on the stock.

BridgeBio Oncology Therapeutics Trading Down 1.0%

Shares of NASDAQ:BBOT opened at $8.95 on Wednesday. The firm has a market capitalization of $717.52 million, a PE ratio of -3.24 and a beta of 0.35. The business’s 50 day moving average is $8.35 and its 200-day moving average is $8.99. BridgeBio Oncology Therapeutics has a 1-year low of $7.00 and a 1-year high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its earnings results on Tuesday, August 11th. The company reported ($705.20) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that BridgeBio Oncology Therapeutics will post -2.32 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Tema ETFs LLC increased its stake in BridgeBio Oncology Therapeutics by 13.6% during the 2nd quarter. Tema ETFs LLC now owns 93,339 shares of the company’s stock worth $711,000 after acquiring an additional 11,167 shares during the period. Avidity Partners Management LP acquired a new position in shares of BridgeBio Oncology Therapeutics in the 1st quarter valued at approximately $392,000. Granahan Investment Management LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics during the 1st quarter worth approximately $2,068,000. Renaissance Technologies LLC raised its position in BridgeBio Oncology Therapeutics by 37.1% during the first quarter. Renaissance Technologies LLC now owns 101,900 shares of the company’s stock valued at $912,000 after purchasing an additional 27,600 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of BridgeBio Oncology Therapeutics by 22.4% in the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after purchasing an additional 5,249 shares in the last quarter. 54.89% of the stock is owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.